Compared with R-CHOP, zanubrutinib plus R-CHOP effectively increased the CR rate of DE-DLBCL and showed a tendency to delay disease progression, especially in DE-DLBCL with Ki67 index >75% or p53 expression >50%. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.